Alfaxan Multidose and Zoletil are among the products obtained by Zoetis.

Australia-based veterinary drug developer Jurox has agreed to a takeover by animal health giant Zoetis Inc. Terms were not disclosed, and the transaction should close in the first half of 2022.

Jurox’s product portfolio includes:

The intravenous anesthetic agents Alfaxan Multidose and Zoletil for cats and dogs.
The sedative and anesthetic Alfaxan Multidose IDX for minor species.
Parasiticides and anti-infectives.

Jurox operates a manufacturing plant in Australia, which U.S.-based Zoetis reported is its fifth-largest market.

“Jurox’s portfolio plays to the strengths of our core business and will be a complementary fit with the solutions we deliver to veterinary professionals, livestock producers and pet owners,” said Zoetis CEO Kristin Peck.

The Australian company is privately owned.

“Beginning as a small Australian family business, we have been able to grow and become a trusted partner to our customers, based on our dedicated people and high-quality products,” said Jurox CFO Gwen O’Brien. “We have come to know Zoetis over the years as a business partner, and this agreement marks an exciting, new chapter in our history, bringing global scale and capabilities to our operations and team.”

Jurox’s U.S. operations are headquartered in Kansas City, Missouri.

Zoetis, with 2020 revenue of $6.7 billion, is the world’s largest animal health company.

Photo credit: istockphoto.com/Chalabala

Zoetis Will Acquire Australian Drug Maker Jurox